Commission Decision of 11 April 2006 on the allocation of quantities of controlled substances allowed for essential uses in the Community in 2006 under Regulation (EC) No 2037/2000 of the European Parliament and of the Council (notified under document number C(2006) 1483) (Only the Danish, Dutch, English, Estonian, Finnish, French, German, Italian, Slovenian, Spanish and Swedish texts are authentic) (Text with EEA relevance) (2006/540/EC)

Commission Decision

of 11 April 2006

on the allocation of quantities of controlled substances allowed for essential uses in the Community in 2006 under Regulation (EC) No 2037/2000 of the European Parliament and of the Council

(notified under document number C(2006) 1483)

(Only the Danish, Dutch, English, Estonian, Finnish, French, German, Italian, Slovenian, Spanish and Swedish texts are authentic)

(Text with EEA relevance)

(2006/540/EC)

THE COMMISSION OF THE EUROPEAN COMMUNITIES,

Having regard to the Treaty establishing the European Community,

Having regard to Regulation (EC) No 2037/2000 of the European Parliament and of the Council of 29 June 2000 on Substances that Deplete the Ozone Layer(1), and in particular Article 3(1) thereof,

Whereas:

(1) The Community has already phased out the production and consumption of chlorofluorocarbons, other fully halogenated chlorofluorocarbons, halons, carbon tetrachloride, 1,1,1-trichloroethane, hydrobromofluorocarbon and bromochloromethane.

(2) Each year the Commission is required to determine essential uses for these controlled substances, the quantities that may be used and the companies that may use them.

(3) Decision IV/25 of the Parties to the Montreal Protocol on Substances that Deplete the Ozone Layer, hereinafter ‘the Montreal Protocol’, sets out the criteria used by the Commission for determining any essential uses and authorises the production and consumption necessary to satisfy essential uses of controlled substances in each Party.

(4) Decision XV/8 of the Parties to the Montreal Protocol authorises the production and consumption necessary to satisfy essential uses of controlled substances listed in Annexes A, B and C (Group II and III substances) of the Montreal Protocol for laboratory and analytical uses as listed in Annex IV to the report of the Seventh Meeting of the Parties, subject to the conditions set out in Annex II to the report of the Sixth Meeting of the Parties, as well as Decisions VII/11, XI/15 and XV/5 of the Parties to the Montreal Protocol.Decision XVII/10 of the Parties to the Montreal Protocol authorises the production and consumption of the controlled substance listed in Annex E of the Montreal Protocol necessary to satisfy laboratory and analytical uses of methyl bromide.

(5) Pursuant to paragraph 3 of Decision XII/2 of the Parties to the Montreal Protocol on measures to facilitate the transition to chlorofluorocarbon-free Metered-Dose Inhalers (MDIs), all Member States have notified(2) the United Nations Environment Programme that chlorofluorocarbons (CFCs) are no longer essential for the manufacture of salbutamol CFC-MDIs for placing on the market of the European Community. Austria, Belgium, Czech Republic, Denmark, Estonia, Germany, Greece, Hungary, Latvia, Lithuania, Norway, Portugal, The Netherlands, the Slovak Republic and Slovenia have notified UNEP that the use of CFCs is not considered essential for the manufacture of MDIs for placing on the market of the European Community that contain the active ingredients belonging to the therapeutic category of ‘short-acting beta agonist bronchiodilators’, specifically terbutaline(3), fenoterol, orciprenaline, reproterol, carbuterol, hexoprenaline, pirbuterol, clenbuterol, bitolterol and procaterol. Belgium, the Czech Republic, Estonia, Germany, Hungary, Latvia, the Netherlands, the Slovak Republic, Slovenia and Sweden have notified UNEP that use of CFCs is not considered essential for the manufacture of MDIs for placing on the market of the European Community that contain the active ingredients belonging to the therapeutic category of ‘inhaled steroids’, specifically beclomethasone, dexamethasone, flunisolide, fluticasone, budesonide(4) and triamcinolone. Denmark (beclomethasone, fluticasone), Ireland (beclomethasone, fluticasone), Finland (beclomethasone, fluticasone), France (beclomethasone, fluticasone), Italy (beclomethasone, fluticasone, budesonide), Malta (fluticasone, budesonide), Portugal (fluticasone, budesonide), Slovenia (beclomethasone, fluticasone, budesonide), Spain (beclomethasone, fluticasone) and the United Kingdom (fluticasone) have notified UNEP that use of CFCs is not considered essential for the manufacture of MDIs for placing on the market of the European Community that contain the active ingredients belonging to the therapeutic category of ‘inhaled steroids’ shown in parentheses after each Member State. Belgium, the Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Latvia, the Netherlands, the Slovak Republic and Slovenia have notified UNEP that use of CFCs is not considered essential for the manufacture of MDIs for placing on the market of the European Community that contain the active ingredients belonging to the therapeutic category of ‘non-steroidal anti-inflammatories’, specifically cromoglicic acid and nedrocromil. Portugal has notified UNEP that use of CFCs is not considered essential for the manufacture of MDIs for placing on the market of the European Community that contains the active ingredient cromoglicic acid. Spain has notified UNEP that use of CFCs is not considered essential for the manufacture of MDIs for placing on the market of the European Community that contains the active ingredient nedrocromil. Belgium, Cyprus, the Czech Republic, Denmark, Estonia, Finland, Germany, Greece, Hungary, Ireland, Latvia, Malta, the Netherlands, the Slovak Republic, Spain, Sweden and the United Kingdom have notified UNEP that use of CFCs is not considered essential for the manufacture of MDIs for placing on the market of the European Community that contain the active ingredients belonging to the therapeutic category of ‘anticholinergic bronchodilators’, specifically ipatropium bromide and oxitropium bromide. Portugal has notified UNEP that use of CFCs is not considered essential for the manufacture of MDIs for placing on the market of the European Community that contains the active ingredient ipatropium bromide. Germany has notified UNEP that use of CFCs is not considered essential for the manufacture of MDIs for placing on the market of the European Community that contain the active ingredients belonging to the therapeutic category of ‘long-acting beta agonist bronchiodilators’, specifically formoterol and salmeterol. Italy has notified UNEP that use of CFCs is not considered essential for the manufacture of MDIs for placing on the market of the European Community that contains the active ingredient formoterol. Germany and the Netherlands have notified UNEP that use of CFCs is not considered essential for the manufacture of MDIs for placing on the market of the European Community that contain combinations of active ingredients. Article 4(4)(i)(b) of Regulation (EC) No 2037/2000 prevents CFCs from being used and placed on the market unless they are considered essential under the conditions described in Article 3(1) of that Regulation. These non-essentiality determinations have therefore reduced the demand for CFCs used in MDIs that are placed on the market of the European Community. In addition, Article 4(6) of Regulation (EC) No 2037/2000 prevents CFC-MDI products being imported and placed on the market unless the CFCs in these products are considered essential under the conditions described in Article 3(1).

(6) The Commission has published a Notice(5) on 8 July 2005 to those companies in the Community of 25 Member States that request consideration by the Commission for the use of controlled substances for essential uses in the Community in 2006 and has received declarations on intended essential uses of controlled substances for 2006.

(7) For the purpose of ensuring that interested companies and operators may continue to benefit in due time from the licensing system, it is appropriate that the present decision shall apply from 1 January 2006.

(8) The measures provided for in this Decision are in accordance with the opinion of the Management Committee established by Article 18(1) of Regulation (EC) No 2037/2000,

HAS ADOPTED THIS DECISION:

Article 1 U.K.

1. The quantity of controlled substances of Group I (chlorofluorocarbons 11, 12, 113, 114 and 115) subject to Regulation (EC) No 2037/2000 which may be used for essential medical uses in the Community in 2006 shall be 539 000,0 ODP(6) kilograms.

2. The quantity of controlled substances of Group I (chlorofluorocarbons 11, 12, 113, 114 and 115) and Group II (other fully halogenated chlorofluorocarbons) subject to Regulation (EC) No 2037/2000 which may be used for essential laboratory uses in the Community in 2006 shall be 256 761,86 ODP kilograms.

3. The quantity of controlled substances of Group III (halons) subject to Regulation (EC) No 2037/2000 that may be used for essential laboratory use in the Community in 2006 shall be 482,70 ODP kilograms.

4. The quantity of controlled substances of Group IV (carbon tetrachloride) subject to Regulation (EC) No 2037/2000 that may be used for essential laboratory uses in the Community in 2006 shall be 149 641,536 ODP kilograms.

5. The quantity of controlled substances of Group V (1,1,1-trichloroethane) subject to Regulation (EC) No 2037/2000 that may be used for essential laboratory uses in the European Union in 2006 shall be 754,00 ODP kilograms.

6. The quantity of controlled substances of Group VI (methyl bromide) subject to Regulation (EC) No 2037/2000 that may be used for laboratory and analytical uses in the Community in 2006 shall be 300,00 ODP kilograms.

7. The quantity of controlled substances of Group VII (hydrobromofluorocarbons) subject to Regulation (EC) No 2037/2000 that may be used for essential laboratory uses in the Community in 2006 shall be 4,49 ODP kilograms.

8. The quantity of controlled substances of group IX (bromochloromethane) subject to Regulation (EC) No 2037/2000 that may be used for essential laboratory uses in the Community in 2006 shall be 13,308 ODP kilograms.

Article 2 U.K.

The chlorofluorocarbon metered-dose inhalers listed in Annex I shall not be placed on markets where the Competent Authority has determined chlorofluorocarbonsfor metered-dose inhalers on those markets to be non-essential.

Article 3 U.K.

During the period 1 January to 31 December 2006 the following rules shall apply:

1.

The allocation of essential medical use quotas for chlorofluorocarbons 11, 12, 113, 114 and 115 shall be to the companies indicated in Annex II.

2.

The allocation of essential laboratory use quotas for chlorofluorocarbons 11, 12, 113, 114 and 115 and other fully halogenated chlorofluorocarbons shall be to the companies indicated in Annex III.

3.

The allocation of essential laboratory use quotas for halons shall be to the companies indicated in Annex IV.

4.

The allocation of essential laboratory use quotas for carbon tetrachloride shall be to the companies indicated in Annex V.

5.

The allocation of essential laboratory use quotas for 1,1,1-trichloroethane shall be to the companies indicated in Annex VI.

6.

The allocation of laboratory and analytical critical use quotas for methyl bromide shall be to the companies indicated in Annex VII.

7.

The allocation of essential laboratory use quotas for hydrobromofluorocarbons shall be to the companies indicated in Annex VIII.

8.

The allocation of essential laboratory use quotas for bromochloromethane shall be to the companies indicated in Annex IX.

9.

The essential use quotas for chlorofluorocarbons 11, 12, 113, 114 and 115, other fully halogenated chlorofluorocarbons, carbon tetrachloride, 1,1,1-trichloroethane, hydrobromofluorocarbons and bromochloromethane shall be as set out in Annex X.

Article 4 U.K.

This Decision shall apply from 1 January 2006 and shall expire on 31 December 2006.

Article 5 U.K.

This Decision is addressed to the following undertakings:

• 3M Health Care Ltd

  3M House Morley Street

  Loughborough

  Leicestershire LE11 1EP

  United Kingdom

• Bespak PLC

  North Lynn Industrial Estate

  King's Lynn

  PE30 2JJ — Norfolk

  United Kingdom

• Boehringer Ingelheim GmbH

  Binger Straße 173

  D-55216 Ingelheim am Rhein

  on behalf of Boehringer Ingelheim (France)

• Chiesi Farmaceutici SpA

  Via Palermo, 26/A

  I-43100 Parma

• IVAX Ltd

  Unit 301 Industrial Park

  Waterford

  Ireland

• Laboratorio Aldo Union SA

  Baronesa de Maldá, 73

  Espluges de Llobregat

  E-08950 Barcelona

• SICOR SpA

  Via Terrazzano, 77

  I-20017 Rho (MI)

• Valeas SpA Pharmaceuticals

  Via Vallisneri, 10

  I-20133 Milano

• Valvole Aerosol Research Italiana (VARI)

  Spa — LINDAL Group Italia

  Via del Pino, 10

  I-23854 Olginate (LC)

• Acros Organics bvba

  Janssen Pharmaceuticalaan 3^o

  B-2440 Geel

• Airbus France

  route de Bayonne 316

  F-31300 Toulouse

• Biosolove B.V.

  Waalreseweg 17

  5554 HA Valkenswaard

  Nederland

• Bie & Berntsen

  Sandbækvej 7

  DK-2610 Roedovre

• Carlo Erba Reactifs-SDS

  Z.I. de Valdonne, BP 4

  F-13124 Peypin

• CNRS — Groupe de Physique des Solides

  Université Paris, 7 Denis Diderot & Paris

  6 Pierre et Marie Curie

  F-75251 Paris Cedex 5

• Health Protection Inspectorate-Laboratories

  Paldiski mnt 81

  EE-10617 Tallinn

• Honeywell Fluorine Products Europe

  Kempenweg 90

  P.O. Box 264

  6000 AG Weert

  Nederland

• Honeywell Specialty Chemicals

  Wunstorfer Straße 40

  Postfach 100262

  D-30918 Seelze

• Ineos Fluor Ltd

  PO Box 13, The Heath

  Runcorn Cheshire WA7 4QF

  United Kingdom

• Institut Scientifique de Service Public (ISSeP)

  Rue du Chéra, 200

  B-4000 Liège

• Katholieke Universiteit Leuven

  Krakenstraat 3

  B-3000 Leuven

• LGC Promochem GmbH

  Mercatorstraße 51

  D-46485 Wesel

• Mallinckrodt Baker BV

  Teugseweg 20

  7418 AM Deventer

  Nederland

• Merck KgaA

  Frankfurter Straße 250

  D-64271 Darmstadt

• Mikro+Polo d.o.o.

  Lackova 78

  SLO-2000 Maribor

• Ministry of Defense

  Directorate Material RNL Navy

  PO Box 2070

  2500 ES The Hague

  Nederland

• Panreac Química SA

  Riera de Sant Cugat 1

  E-08110 Montcada I Reixac (Barcelona)

• Sanolabor d.d.

  Leskovškova 4

  SLO-1000 Ljubljana

• Sigma Aldrich Logistik GmbH

  Riedstraße 2

  D-89555 Steinheim

• Sigma Aldrich Chimie SARL

  80, rue de Luzais

  L'isle-d'abeau Chesnes

  F-38297 Saint-Quentin-Fallavier

• Sigma Aldrich Company Ltd

  The Old Brickyard

  New Road Gillingham SP8 4XT

  United Kingdom

• Sigma Aldrich Laborchemikalien

  Wunstorfer Straße 40

  Postfach 100262

  D-30918 Seelze

• Sigma Aldrich Chemie GmbH

  Riedstraße 2

  D-89555 Steinheim

• Tazzetti Fluids S.r.l.

  Corso Europa, 600/a

  I-10088 Volpiano (TO)

• University of Technology Vienna

  Institut of Industrial Electronics&Material Science

  Gusshausstraße 27-29

  A-1040 Wien

• VWR I.S.A.S.

  201, rue Carnot

  F-94126 Fontenay-sous-Bois

• YA-Kemia Oy — Sigma Aldrich Finland

  Teerisuonkuja 4

  FI-00700 Helsinki

Done at Brussels, 11 April 2006.

For the Commission

Stavros Dimas

Member of the Commission

ANNEX I U.K.

Pursuant to paragraph 3 of Decision XII/2 of the Twelfth Meeting of the Parties to the Montreal Protocol on measures to facilitate the transition to chlorofluorocarbon-free metered-dose inhalers (MDIs), the following countries have determined that, due to the presence of suitable non-CFC MDIs, CFCs no longer qualify as ‘essential’ under the Protocol when combined with following active ingredients:

Table 1

Source: www.unep.org/ozone/Information_for_the_Parties/3Bi_dec12-2-3.asp
Country	Short-acting Beta Agonist Bronchodilators
	Salbutamol	Terbutaline	Fenoterol	Orciprenaline	Reproterol	Carbuterol	Hexoprenaline	Pirbuterol	Clenbuterol	Bitolterol	Procaterol
Austria	X	X	X	X	X	X	X	X	X	X	X
Belgium	X	X	X	X	X	X	X	X	X	X	X
Cyprus	X
Czech Republic	X	X	X	X	X	X	X	X	X	X	X
Denmark	X		X	X	X	X	X	X	X	X	X
Estonia	X	X	X	X	X	X	X	X	X	X	X
Finland	X
France	X
Germany	X	X	X	X	X	X	X	X	X	X	X
Greece	X	X	X	X	X	X	X	X	X	X	X
Hungary	X	X	X	X	X	X	X	X	X	X	X
Ireland	X
Italy	X
Latvia	X	X	X	X	X	X	X	X	X	X	X
Lithuania	X	X	X	X	X	X	X	X	X	X	X
Luxembourg	X
Malta	X
Netherlands	X	X	X	X	X	X	X	X	X	X	X
Poland	X
Portugal	X	X	X	X	X	X	X	X	X	X	X
Norway	X	X	X	X	X	X	X	X	X	X	X
Slovak Republic	X	X	X	X	X	X	X	X	X	X	X
Slovenia	X	X	X	X	X	X	X	X	X	X	X
Spain	X
Sweden	X
United Kingdom	X

Table 2

Source: www.unep.org/ozone/Information_for_the_Parties/3Bi_dec12-2-3.asp
Country	Inhaled steroids
	Beclomethasone	Dexamethasone	Flunisolide	Fluticasone	Budesonide	Triamcinolone
Austria
Belgium	X	X	X	X	X	X
Cyprus
Czech Republic	X	X	X	X	X	X
Denmark	X			X
Estonia	X	X	X	X	X	X
Finland	X			X
France	X			X
Germany	X	X	X	X	X	X
Greece
Hungary	X	X	X	X	X	X
Ireland	X			X
Italy	X			X	X
Latvia	X	X	X	X	X	X
Lithuania
Luxembourg
Malta				X	X
Poland
Portugal				X	X
Netherlands	X	X	X	X	X	X
Norway
Slovak Republic	X	X	X	X	X	X
Slovenia	X	X	X	X	X	X
Spain	X			X
Sweden	X	X	X	X		X
United Kingdom				X

Table 3

Source: www.unep.org/ozone/Information_for_the_Parties/3Bi_dec12-2-3.asp
Country	Non-steroidal anti-inflammatories
	Cromoglicic acid	Nedrocromil
Austria
Belgium	X	X
Cyprus
Czech Republic	X	X
Denmark	X	X
Estonia	X	X
Finland	X	X
France	X	X
Germany	X	X
Greece	X	X
Hungary
Ireland
Italy
Latvia	X	X
Lithuania
Luxembourg
Malta
Poland
Portugal	X
Netherlands	X	X
Norway
Slovak Republic	X	X
Slovenia	X	X
Spain		X
Sweden
United Kingdom

Table 4

Source: www.unep.org/ozone/Information_for_the_Parties/3Bi_dec12-2-3.asp
Country	Anticholinergic Bronchodilators
	Ipratropium bromide	Oxitropium Bromide
Austria
Belgium	X	X
Cyprus	X	X
Czech Republic	X	X
Denmark	X	X
Estonia	X	X
Finland	X	X
France
Germany	X	X
Greece	X	X
Hungary	X	X
Ireland	X	X
Italy
Latvia
Lithuania
Luxembourg
Malta	X	X
Netherlands	X	X
Poland
Portugal	X
Norway
Slovak Republic	X	X
Slovenia
Spain	X	X
Sweden	X	X
United Kingdom	X	X

Table 5

Source: www.unep.org/ozone/Information_for_the_Parties/3Bi_dec12-2-3.asp
Country	Long-acting Beta Agonist Bronchodilators
	Formoterol	Salmeterol
Austria
Belgium
Cyprus
Czech Republic
Denmark
Estonia
Finland
France
Germany	X	X
Greece
Hungary
Ireland
Italy	X
Latvia
Lithuania
Luxembourg
Malta
Netherlands
Poland
Portugal
Norway
Slovak Republic
Slovenia
Spain
Sweden
United Kingdom

Table 6

Source: www.unep.org/ozone/Information_for_the_Parties/3Bi_dec12-2-3.asp
Country	Combinations of active ingredients in a single MDI
Austria
Belgium
Cyprus
Czech Republic
Denmark
Estonia
Finland
France
Germany	X
Greece
Hungary
Ireland
Italy
Latvia
Lithuania
Luxembourg
Malta
Netherlands
Poland
Portugal
Norway
Slovak Republic
Slovenia
Spain
Sweden
United Kingdom

ANNEX II U.K. ESSENTIAL MEDICAL USES

Quota of controlled substances of Group I that may be used in the production of metered dose inhalers (MDIs) for the treatment of asthma and other chronic obstructive pulmonary diseases (COPDs) are allocated to:

• 3M Health Care (UK)

• Bespak (UK)

• Boehringer Ingelheim (DE) on behalf of Boehringer Ingelheim France

• Chiesi (IT)

• IVAX (IE)

• Lab Aldo-Union (ES)

• Sicor (IT)

• Valeas (IT)

• V.A.R.I. (IT)

ANNEX III U.K. ESSENTIAL LABORATORY USES

Quota of controlled substances of Group I and II that may be used for laboratory and analytical uses, are allocated to:

• Acros organics bvba (BE)

• Bie & Berntsen (DK)

• Biosolve (NL)

• Carlo Erba Reactifs-SDS (FR)

• CNRS — Groupe de Physique des Solides (FR)

• Honeywell Fluorine Products Europe (NL)

• Honeywell Specialty Chemicals (DE)

• Ineos Fluor (UK)

• Katholieke Universiteit Leuven (BE)

• LGC Promochem (DE)

• Mallinckrodt Baker (NL)

• Merck KGaA (DE)

• Mikro + Polo (SI)

• Panreac Química (ES)

• Sanolabor (SI)

• Sigma Aldrich Chimie (FR)

• Sigma Aldrich Company (UK)

• Sigma Aldrich Logistik (DE)

• Tazzetti Fluids (IT)

• University of Technology Vienna (AT)

ANNEX IV U.K. ESSENTIAL LABORATORY USES

Quota of controlled substances of Group III that may be used for laboratory and analytical uses are allocated to:

• Airbus France (FR)

• Ineos Fluor (UK)

• Ministry of Defense (NL)

• Sigma Aldrich Chimie (FR)

ANNEX V U.K. ESSENTIAL LABORATORY USES

Quota of controlled substances of Group IV that may be used for laboratory and analytical uses, are allocated to:

• Acros Organics (BE)

• Bie & Berntsen (DK)

• Biosolve (NL)

• Carlo Erba Reactifs-SDS (FR)

• Health Protection Inspectorate-Laboratories (EE)

• Institut Scientifique de Service Public (ISSeP) (BE)

• Katholieke Universiteit Leuven (BE)

• Mallinckrodt Baker (NL)

• Merck KGaA (DE)

• Mikro + Polo (SI)

• Panreac Química (ES)

• Sanolabor d.d. (SI)

• Sigma Aldrich Chimie (FR)

• Sigma Aldrich Company (UK)

• Sigma Aldrich Laborchemikalien (DE)

• Sigma Aldrich Logistik (DE)

• VWR I.S.A.S. (FR)

• YA-Kemia Oy (FI)

ANNEX VI U.K. ESSENTIAL LABORATORY USES

Quota of controlled substances of Group V that may be used for laboratory and analytical uses are allocated to:

• Acros Organics (BE)

• Bie & Berntsen (DK)

• Katholieke Universiteit Leuven (BE)

• Mallinckrodt Baker (NL)

• Merck KGaA (DE)

• Mikro + Polo (SI)

• Panreac Química (ES)

• Sanolabor d.d. (SI)

• Sigma Aldrich Chimie (FR)

• Sigma Aldrich Company (UK)

• Sigma Aldrich Logistik (DE)

• YA-Kemia Oy (FI)

ANNEX VII U.K. LABORATORY AND ANALYTICAL CRITICAL USES

Quota of controlled substances of Group VI that may be used for laboratory and analytical critical uses are allocated to:

Sigma-Aldrich Chemie GmbH (DE)

ANNEX VIII U.K. ESSENTIAL LABORATORY USES

Quota of controlled substances of Group VII that may be used for laboratory and analytical uses are allocated to:

• Ineos Fluor (UK)

• Katholieke Universiteit Leuven (BE)

• Sigma Aldrich Logistik (FR)

• Sigma Aldrich Company (UK)

ANNEX IX U.K. ESSENTIAL LABORATORY USES

Quota of controlled substances of Group IX that may be used for laboratory and analytical uses are allocated to:

• Ineos Fluor (UK)

• Katholieke Universiteit Leuven (BE)

• Sigma Aldrich Logistik (FR)

• YA-Kemia Oy (FI)

ANNEX X U.K.

[This Annex is not published because it contains confidential commercial information.]

(1)

OJ L 244, 29.9.2000, p. 1. Regulation as last amended by Commission Regulation (EC) No 29/2006 (OJ L 6, 11.1.2006, p. 27).

(2)

www.unep.org/ozone/Information_for_the_Parties/3Bi_dec12-2-3.asp

(3)

Except Denmark.

(4)

Except Sweden.

(5)

OJ C 168, 8.7.2005, p. 20.

(6)

Ozone-depleting Potential.